Compare BridgeBio Pharma Inc (BBIO) vs Tencent Music Entertainment Group - ADR (TME) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Tencent Music Entertainment Group - ADR — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Tencent Music Entertainment Group - ADR trades at $8.65 (market cap $15.69B). The key difference: BridgeBio Pharma Inc and Tencent Music Entertainment Group - ADR are close in size by market cap, and Tencent Music Entertainment Group - ADR pays a 2.42% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | TME | |
|---|---|---|
Market Cap | $16.61B | $15.69B |
Sector | Health | Media |
52-Week High | $90.17 | $26.36 |
52-Week Low | $47.29 | $8.16 |
Enterprise Value | $18.16B | $12.45B |
Dividend Yield | — | 2.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
TME trades at $9.53, down 0.63% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong 2025 revenue of $32.90B and net income of $11.06B, with a P/E of 11.33 indicating reasonable valuation. Recent news highlights institutional buying and strategic moves like the Ximalaya acquisition to bolster ecosystem dominance.
Outlook is cautiously optimistic with a consensus price target of $14.00, offering 47% upside. Risks include competitive pressures and AI-driven copyright challenges, but solid profitability and Tencent backing provide resilience. The stock presents a value opportunity if execution on premiumization continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Tencent Music Entertainment Group - ADR
TME is the largest online music service provider in China. It was founded in 2016 with the business combination of QQ Music (founded in 2005), Kuwo Music (founded in 2005) and Kugou Music (founded in 2004) streaming platforms. Tencent is the largest shareholder of TME with over 50% shares and over 90% voting rights held. TME also provides social entertainment services, including music live audio/video broadcasts and online concert services through the three platforms mentioned above, and online karaoke through an independent platform WeSing.
Read more on TME →
